Presentation Alert: Aethlon CEO to Present at Today's International Human and Avian Influenza Pandemic Symposium

Business Wire, Oct 6, 2006

SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing therapeutic devices for infectious disease, announced that its Chairman & CEO, James A. Joyce will present today at "The International Avian and Human Influenza Pandemic Symposium" being held at the Italian Embassy in Washington, DC. Mr. Joyce will present at 11:30am EST.

"Aethlon Medical is honored to be the sole public market representative invited to take part in this prestigious event," stated Mr. Joyce. "Our Hemopurifier(TM) technology offers to fill the void in treating emerging threats that are resistant to drug and vaccine therapy," concluded Joyce. Other speakers include:

Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S. Department of Health and Human Services (NIH, NIAID, HHS)

Ambassador John E. Lange, Avian Influenza Action Group (AIAG), U.S. Department of State

Honorable Alex Azar, Deputy Secretary, Dept. of Health and Human Services (HHS)

His Excellency Giovanni Castellaneta, Ambassador of the Republic of Italy to the United States

His Excellency, Jean-David Levitte, Ambassador of France to the United States

His Excellency, Angelos Pangratis, Minister and Deputy Head, European Commission Delegation to the United States

Nadia Naffakh, Unite de Genetique Moleculaire des Virus Respiratoires, Institute Pasteur, Paris, France

Toni Scarpa, Director of the Center for Scientific Review, National Institutes of Health (NIH)

James W. Leduc, Centers for Disease Control and Prevention (CDC)

Helen Karuso, Bioexpert, Embassy of Australia, Washington DC

Michael Callahan, Director, Bio-defense and Mass Casualty Care, CIMIT/Massachusetts General Hospital/Harvard Medical School Advisor, U.S. Dept of State Bio-Engagement Program-S.E. Asia

Dr Stephen Morse, Founding Director, Center for Public Health Preparedness, Mailman School of Health, Columbia University, New York

Peter Uthoff, Director, Office of Public Health Security, Public Health Agency of Canada

James Kvach, Chief Scientist, Defense Intelligence Agency, Armed Forces, Medical Intelligence Center

Rashid A. Chotani, Senior Science Advisor, Chemical and Biological Defense Directorate, Joint Science and Technology Office, Defense Threat Reduction Agency (DTRA)

About Aethlon Medical

Aethlon Medical has developed the first-in-class medical device to treat infectious disease. The device, known as the Hemopurifier[TM], is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Global researcher, Frost & Sullivan, recently awarded the Hemopurifier(TM) the 2006 Technology Innovation Award for its advances in the field of biodefense. Aethlon has also initiated research on a second generation Hemopurifier(TM) that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.